EU's CHMP endorses Novartis's Menveo
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that Novartis's conjugated vaccine Menveo (meningococcal group A, C, W-135 and Y-CRM conjugate vaccine) be approved for the immunisation of people aged over 11 years at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.